Acrotac 10mg Capsule (Acitretin)

Description

Acrotac 10mg Capsule (Acitretin) — Complete Clinical and Patient Information Guide

Product Overview

Acrotac 10mg Capsule (Acitretin) contains Acitretin 10mg as its active pharmaceutical ingredient, belonging to the systemic oral retinoid — second-generation aromatic retinoid. It is clinically indicated for severe plaque psoriasis and generalised pustular psoriasis unresponsive to topical therapy, keratinisation disorders including ichthyoses, palmoplantar keratoderma, Darier’s disease, and pityriasis rubra pilaris. This comprehensive guide has been developed in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines to provide accurate, evidence-based information for patients and healthcare professionals.

Acrotac 10mg provides acitretin at the 10mg dose. Acrotac 10mg provides the initial low dose for treatment titration, the dose used in patients requiring minimal effective dose strategies, or for maintenance in patients who achieved response at higher doses. Acitretin is one of a small number of systemic options for severe psoriasis and is uniquely valuable for pustular psoriasis (both generalised and palmoplantar), for which many biologic agents have limited evidence, and for the rare keratinisation disorders where it remains the most effective available systemic treatment.

Understanding Acrotac 10mg and Its Active Ingredient

Acitretin 10mg is the pharmacologically active compound in Acrotac 10mg. The drug class to which it belongs — systemic oral retinoid — second-generation aromatic retinoid — has a well-established clinical evidence base developed across decades of research, regulatory review, and real-world clinical use. Understanding the mechanism of action, appropriate therapeutic use, necessary monitoring, and safety considerations of this medication is essential for achieving optimal clinical outcomes while protecting patient safety.

This product should only be used under appropriate medical supervision. For medications classified as YMYL (conditions where improper use carries significant health risk), professional medical guidance before initiating, modifying, or stopping therapy is not optional — it is a fundamental patient safety requirement. Patients are encouraged to maintain open, honest communication with their prescribing physician and pharmacist about all aspects of their treatment.

Mechanism of Action

Acitretin is a second-generation, aromatic, monoaromatic retinoid and the active metabolite of etretinate. As a systemic oral retinoid, it binds to retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma) in keratinocytes throughout the body, modulating transcription of genes governing epidermal differentiation, proliferation, and cornification. In psoriasis, the epidermal transit time is compressed from the normal 28 days to 3–4 days, producing the characteristic hyperproliferative, inflammatory plaque. Acitretin normalises this aberrant differentiation programme — restoring the normal rate of keratinocyte maturation, reducing keratinocyte hyperproliferation, and suppressing the pro-inflammatory cytokine milieu (IL-17, IL-23, TNF-alpha) characteristic of psoriatic plaques. For keratinisation disorders (ichthyoses, Darier’s disease, palmoplantar keratoderma), the drug directly corrects the abnormal cornification signals by restoring normal RAR-mediated gene transcription in keratinocytes. Acitretin’s anti-inflammatory properties are secondary to its primary effect on keratinocyte biology: as the epidermis normalises, the associated inflammatory infiltrate and cytokine production subsides. Unlike biologic agents targeting specific cytokines, acitretin acts as a broad normaliser of epidermal biology, making it effective across a range of hyperproliferative skin diseases beyond psoriasis.

Understanding how this medication works at the molecular and cellular level helps explain the clinical requirements for optimal use: why specific timing, administration conditions, monitoring tests, contraindications, and drug interactions exist. Healthcare providers apply this mechanistic understanding to individualise therapy, anticipate drug interactions, counsel patients on what to expect, and monitor for treatment response and toxicity.

Clinical Indications

Acrotac 10mg Capsule (Acitretin) is clinically indicated for:

• Primary indication: severe plaque psoriasis and generalised pustular psoriasis unresponsive to topical therapy, keratinisation disorders including ichthyoses, palmoplantar keratoderma, Darier’s disease, and pityriasis rubra pilaris
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of this specific medication for the individual patient. Self-diagnosis and self-treatment with prescription medications carries significant and potentially serious health risks.
• Treatment goals and monitoring: The prescribing physician establishes clear therapeutic objectives and a monitoring plan appropriate to the specific indication and the patient’s individual risk profile.

Dosage and Administration

Acitretin dosing is highly individualised. Typical starting dose: 25–30mg once daily with the main meal (fat-soluble drug). Maintenance: 25–50mg daily based on individual response and tolerability. 10mg is a component of the prescribed regimen — never alter without specialist dermatologist guidance. Treatment is typically administered in courses of 3–6 months with reassessment every 3 months. Some patients require ongoing maintenance therapy under regular monitoring.

Adherence to the prescribed dosing regimen is critical for therapeutic success and patient safety. Patients uncertain about their dosing schedule should contact their prescribing physician or pharmacist before making any changes. Never alter doses or stop therapy without medical advice, particularly for medications (such as systemic retinoids, alcohol dependence therapies, and corticosteroids) where abrupt changes can have significant consequences.

Who Should Use Acrotac 10mg

Acrotac 10mg is indicated for adult patients (and where specified, adolescent patients) who have been diagnosed by a qualified healthcare professional with the conditions listed in the indications section, and for whom this medication has been determined appropriate following assessment of individual benefits and risks. Patients should have no absolute contraindications and should be able to comply with any required monitoring or safety programme requirements.

Contraindications — Who Should Not Use Acrotac 10mg

Pregnancy — ABSOLUTE CONTRAINDICATION. Women must avoid pregnancy during treatment AND for 3 years after stopping acitretin (due to potential re-esterification to the longer-persisting etretinate, particularly with concurrent alcohol consumption). Breastfeeding. Hypersensitivity to acitretin, retinoids, or parabens. Severe hepatic or renal impairment. Concurrent methotrexate (hepatotoxicity). Concurrent tetracyclines (pseudotumour cerebri). Vitamin A supplements. Alcohol (re-esterification to etretinate extends the teratogenic risk period beyond 3 years — strictly avoided during and 2 months after treatment). Hypervitaminosis A.

Before starting Acrotac 10mg, patients must provide their prescribing physician with a complete medical history, including all current medications (prescription and over-the-counter), known allergies, and relevant personal and family medical history. Conditions that appear unrelated to the treatment indication may significantly affect prescribing decisions for drugs with complex safety profiles.

Drug Interactions

Tetracyclines — intracranial hypertension risk (absolute contraindication). Methotrexate — hepatotoxicity risk (avoid combination). Vitamin A — hypervitaminosis A. Alcohol — re-esterification to etretinate (avoid completely). Progestogen-only contraceptive (mini-pill) — possible reduced efficacy; two contraception methods mandatory. Ciclosporin — potential additive hepatotoxicity and drug interactions. Phenytoin — protein binding displacement. St John’s Wort — reduces contraceptive pill efficacy.

Drug interactions can be clinically significant and potentially dangerous. A complete medication review by a qualified pharmacist or physician is essential before starting Acrotac 10mg. Many interactions can be effectively managed through dose adjustment, temporal separation of doses, or alternative drug selection — but only when proactively identified. Patients should never add new medications (including herbal supplements and over-the-counter products) without checking for interactions with Acrotac 10mg.

Adverse Effects and Side Effects

Universal: mucocutaneous dryness (dry lips, skin, eyes, nasal mucosa) — intensive moisturisation and lip care essential. Common: elevated triglycerides and cholesterol (requires fasting lipid monitoring), elevated liver transaminases, hair thinning (common, usually reversible), photosensitivity (SPF 50+ mandatory), night blindness (avoid driving in dark if affected). Skeletal effects with long-term high-dose use: hyperostosis, ligament calcification. Paronychia (nail fold inflammation). Psychiatric effects (rare — monitor mood). Severe skin reactions.

Side effects vary in frequency, severity, and clinical significance. Patients should be educated before starting treatment about which side effects to expect and manage (expected retinisation with retinoids, mucocutaneous dryness with isotretinoin) versus which require prompt medical attention (signs of disulfiram-ethanol reaction, symptoms of pseudotumour cerebri, signs of hepatotoxicity). A proactive approach to side-effect education significantly improves treatment adherence and patient safety.

Special Population Considerations

Pregnancy: Isotretinoin and oral acitretin are absolutely contraindicated in pregnancy. Topical retinoids are avoided as a precaution. Topical clindamycin, BPO, and azelaic acid are generally considered safe in pregnancy with appropriate medical guidance. Hydroquinone should be avoided in pregnancy.

Sun protection: All patients on topical retinoids, hydroquinone, doxycycline, or oral retinoids must use daily broad-spectrum SPF 30+ sunscreen. Photosensitivity significantly increases acne scar risk and undermines the efficacy of depigmenting therapies.

Paediatric use: Isotretinoin can be used in adolescents under specialist supervision. Tetracyclines (doxycycline, minocycline) are contraindicated under 8 years. Adapalene is approved in adolescents ≥9 years. Early, effective acne treatment in adolescents is important to prevent permanent scarring.

Darker skin phototypes (Fitzpatrick IV–VI): Post-inflammatory hyperpigmentation is more pronounced and persistent in darker skin — early effective treatment of inflammatory acne is critically important to prevent PIH. Introduce topical retinoids slowly to minimise irritation-related PIH.

Teratogenicity and contraception: The 3-year post-treatment contraception requirement for acitretin (vs 1 month for isotretinoin) reflects the prolonged teratogenic risk from potential re-esterification to etretinate — particularly in patients who consume alcohol. Women must not become pregnant during this 3-year window. Abstaining from alcohol throughout treatment and for 2 months after stopping significantly limits etretinate conversion.

Monitoring schedule: LFTs and fasting lipids before treatment, at 1 month, then every 3 months. Ophthalmological review if visual symptoms develop. Skeletal X-rays in long-term users.

Storage and Handling

Store Acrotac 10mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat sources, and moisture. Keep in the original manufacturer’s packaging until required. Secure out of reach of children and pets. Do not use beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back services — do not flush down drains or discard in household waste, as pharmaceutical waste poses environmental hazards.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children and pets. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Never double-dose. Consult your prescriber if uncertain about how to manage a missed dose in your specific regimen.

Q: Why is the contraception requirement 3 years for acitretin but only 1 month for isotretinoin?
A: Acitretin can be converted (re-esterified) by the liver back to etretinate — a drug with a half-life of 80–160 days (compared to acitretin’s 50 hours). Etretinate accumulates in adipose tissue and can persist for years. Because etretinate is highly teratogenic and persists much longer than acitretin itself, a 3-year contraception window is required to ensure complete elimination before pregnancy. Alcohol accelerates this re-esterification — strict alcohol avoidance reduces the risk.

Q: Can I use acitretin long-term?
A: Some patients with chronic psoriasis or keratinisation disorders require ongoing acitretin therapy. Long-term use requires regular monitoring for skeletal effects (spinal hyperostosis, ligament calcification) with periodic X-rays, liver function monitoring, and lipid management. The benefits must be regularly reassessed against cumulative risks in individual patients.

Clinical Evidence and Quality Standards

The active ingredient in Acrotac 10mg has been evaluated in randomised controlled trials, meta-analyses, and extensive post-marketing surveillance studies supporting its use in the approved indications. Major international clinical guidelines — including those from the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, National Institute for Health and Care Excellence (NICE), and relevant specialty societies — incorporate this drug class in their evidence-based treatment algorithms, reflecting a high level of clinical confidence in its efficacy and safety profile when used appropriately.

Acrotac 10mg is manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities. GMP certification ensures consistent product quality, identity, strength, purity, and safety across all manufactured batches. Patients should only obtain prescription medications from licensed pharmacies with a valid prescription to ensure they receive authentic, properly stored, regulatory-compliant products.

Important Medical Disclaimer

This product information page is provided for general educational purposes only, developed in accordance with YMYL (Your Money Your Life) content standards. The information presented draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It is not a substitute for professional medical advice, diagnosis, or treatment from a qualified physician, dermatologist, addiction medicine specialist, or pharmacist. Drug therapy decisions must be individualised based on the complete clinical picture, comorbidities, and concurrent medications of each patient. Self-diagnosis and self-treatment of conditions managed by prescription medications can be dangerous and may lead to delayed diagnosis of serious underlying conditions, inappropriate drug use, or preventable adverse events. Always consult a qualified healthcare professional before starting, changing, or stopping this or any medication.